| خلاصه مقاله | Introduction: Multiple Sclerosis (MS) is a chronic inflammatory demyelinating disease affecting the central nervous system (CNS). Despite extensive research, a definitive diagnostic test for MS remains elusive. However, emerging evidence suggests that circulating exosomes hold promise as potential biomarkers for a wide range of human diseases. These extracellular vesicles contain RNA, DNA, and proteins, possess the ability to traverse the blood-brain barrier, and are secreted by various cell types, including those within the CNS. In light of this, our study aims to investigate the utility of cerebrospinal fluid (CSF) and serum exosomal miRNAs as a non-invasive biomarker for the detection and monitoring of relapsing-remitting multiple sclerosis (RRMS).
Materials and Methods: In this study, we collected CSF and serum samples, one ml, from each of the 30 untreated patients diagnosed with RRMS and healthy controls (HCs). Our investigation focused on a panel of specific miRNAs, miR-18a-5p, miR-26b-5p, miR-132-5p, and miR-150-5p, which have been associated with regulating inflammatory responses. Following the isolation of exosomes from CSF and serum samples, we utilized qRT-PCR to perform a comprehensive analysis. The objective was to identify any significant variations in the expression levels of exosomal miRNAs within the CSF and serum samples obtained from RRMS patients.
Results: We identified that 3 out of 4 miRNAs displayed different patterns in RRMS patients compared to HCs. miR-18a-5p with dual pro-inflammatory and anti-inflammatory actions and miR-150-5p with anti-inflammatory action were significantly upregulated in both CSF and serum-derived exosomes of RRMS patients compared to corresponding HCs. Additionally, anti-inflammatory miR-132-5p was significantly downregulated in both CSF and serum-derived exosomes of RRMS patients compared to HCs. However, there was no significant difference in the expression level of miR-26b-5p in CSF and serum exosomes between patients and control groups.
Conclusion: Our findings demonstrate that exosomal miR-18a-5p and miR-150-5p hold promise as potential biomarkers in RRMS. Moreover, the utilization of exosomal biomarkers has the potential to significantly advance the early detection of progressive disease onset, surpassing current clinical approaches and the manifestation of clinical symptoms. To implement this application effectively, longitudinal research is necessary, and further investigations should be conducted based on the preliminary findings to establish longitudinal studies. |